🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Torquay
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Torquay

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC7 Novo Nordisk A/S4 Arrowhead Pharmaceuticals3 Hoffmann-La Roche3 Pfizer2
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
40 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
Novo Nordisk A/S
Phase 3
5,610
Truro, Rhyl, Torquay, Dorchester, Airdrie, Tooting, Isleworth, Norwich
2026-05-11
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Boehringer Ingelheim
Phase 3
670
Cardiff, Leicester, Manchester, Sutton, Torquay
2026-04-13
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 3
900
Torquay, Birmingham, Cambridge, London, Manchester
2026-03-09
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979Obesity
Kailera
Phase 3
1,200
Exeter, Torquay, Weymouth, Glasgow, London, Leicester, Rotherham
2025-12-30
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
Taiho Oncology, Inc.
Phase 3
360
Manchester, Nottingham, Torquay, Cardiff
2025-12-22
Recruiting
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
NCT07282665Clostridoides Difficile Associated Disease
Pfizer
Phase 3
32,500
Newquay, Exeter, Plymouth, Torquay, Preston, Glasgow, Southampton, Blackpool
2025-12-10
Active, closed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642Obesity, Overweight
Novo Nordisk A/S
Phase 3
300
Liskeard, Newquay, Torquay
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759Overweight, Obesity, Type 2 Diabetes
Novo Nordisk A/S
Phase 3
330
Liskeard, Newquay, Torquay, Bushey, London
2025-11-05
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Bath, Leeds, London, Manchester, Torquay
2025-10-22
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Blackburn, Cardiff, Plymouth, Torquay, London, Maidstone, Edinburgh, Manchester
2025-09-28
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
288
Torquay, London, Dundee
2025-04-24
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
869
Plymouth, Torquay, London
2025-04-09
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
2025-03-27
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
Glasgow, London, Torquay
2025-03-11
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
480
Greater London, Liverpool, London, Manchester, Sutton, Torquay
2024-12-16
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
67
Torquay, Truro
2024-11-21
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
Daiichi Sankyo
Phase 3
700
Birmingham, Harrow, London, Maidstone, Manchester, Oxford, Torquay
2024-11-19
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
338
Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay
2024-09-23
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer
Phase 3
444
Torquay, Belfast, Guildford, Cardiff
2024-08-28
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
446
Torpoint, Torquay, Plymouth, London
2024-07-22
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Novo Nordisk A/S
Phase 3
10,000
Truro, Torquay, Bournemouth, Ashford, Blackpool, Harefield, Edinburgh, Glasgow
2024-06-25
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Londonderry, Torquay, London, Nottingham
2024-06-10
Active, closed
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167Head and Neck Squamous Cell Carcinoma
Exelixis
Phase 2/3
600
London, Romford, Manchester, Sutton, Torquay
2024-06-07
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
Merck Sharp & Dohme LLC
Phase 1/2
230
Torquay, London, Glasgow, Manchester
2024-03-28
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3
410
Aberdeen, London, Nottingham, Sutton, Torquay
2024-01-11
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Taiho Oncology, Inc.
Phase 3
285
London, Nottingham, Torquay
2023-12-18
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford
2023-12-18
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Nottingham, Sutton, Torquay, Truro
2023-11-16
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
OncoC4, Inc.
Phase 3
630
Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester
2023-06-28
Active, closed
First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
NCT06398743Colorectal Cancer
Exact Sciences Corporation
Observational
416
Headington, Edinburgh, Birmingham, Worcester, Ipswich, Kidderminster, Redditch, Torquay
2023-06-20
Active, closed
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals
Phase 2
95
Torquay
2022-12-06
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Hoffmann-La Roche
Observational
6,000
Bristol, Bedford, Torquay, Hull, Colchester, Gloucester, London, Maidstone
2022-11-21
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891Cancer
EMD Serono Research & Development Institute, Inc.
Observational
700
Torquay, Huddersfield, Bedford, Birmingham, Bournemouth, Cardiff, Chelsea, Harrow
2022-10-04
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
1,051
Belfast, Bristol, Dundee, Edinburgh, London, Middlesbrough, Poole, Torquay
2022-02-07
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
Phase 3
478
Cornwall, Gloucester, London, Nottingham, Torquay
2021-10-27
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
808
Torquay, London
2021-04-21
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185Urinary Bladder Neoplasms
Merck Sharp & Dohme LLC
Phase 3
520
Rhyl, Torquay, Preston, London, Nottingham, Darlington
2020-05-19
Active, closed
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308Psoriatic Arthritis
AbbVie
Phase 3
964
London, Glasgow, Stafford, Manchester, Metropolitan Borough of Wirral, Portsmouth, Torquay
2019-03-25
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC
Phase 3
765
Blackburn, Lancaster, London, Torquay, Truro, Wolverhampton
2019-01-25
Active, closed
UK Infinity, Post-Market Clinical Follow-up Study
NCT03063593Arthritis, Rheumatoid, Post-traumatic Osteoarthritis, Degenerative Arthritis
Stryker Trauma and Extremities
Observational
500
Torquay, Bournemouth, Bothwell, Oswestry, Sheffield, Nottingham, Bristol, Edinburgh
2016-04-29
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/torquay

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.